Oyster Point Pharma Submits New Drug Application to the U.S. Food and Drug Administration for OC-01 (varenicline) Nasal Spray for the Treatment of Signs and Symptoms of Dry Eye Disease

Brenda Snow
Authentic Patient Voice

David Linetsky
Point-of-Care Marketing

Joey Cohen
Medication Adherence

Suma Ramadas, PhD
Medical Affairs

Amy Giles
Increasing Engagement

Liz Kane
Impactful Strategy

Pat Purcell
Meeting Engagement

Matthew Durham
Omnidynamic Marketing

Paul Theisen
Patient Acquisition

Frank Burrell
Scientific Storytelling

Matt Turner
Patient Affordability

Stacey Gandler
Brand Nourishment

Bud Bilanich
Success Coach

Daniel Sontupe
Market Access